Navigation Links
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference

MALVERN, Pa., June 28, 2007 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. today announced that Mr. Armando Anido, Chief Executive Officer and President, and Mr. Jim Fickenscher, Chief Financial Officer, will participate in the 2007 CEUT Emerging Growth Opportunities Conference to be held July 10 through July 12, 2007 at the Mandarin Oriental Hotel in New York City. Mr. Anido is scheduled to present an overview of the Company and its product pipeline at 4:30 PM Eastern Time on Wednesday, July 11, 2007.

To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com. The replay will be available for 90 days after the event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. AA4500, an injectable collagenase enzyme, is in phase III of development for the treatment of Dupuytren's contracture and is in phase II of development for the treatment of Peyronie's disease and Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) is in phase I of development. The Company is currently seeking a partner to further develop this product candidate. Auxilium has two pain products using its transmucosal film delivery system in pre-clinical development. Auxilium has rights to six additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system, and options to all indications using AA4500 for non-topical formulations. For additional info
'"/>




Page: 1 2 3

Related medicine technology :

1. Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014  Novation, the leading health care supply ... IT value-added reseller (VAR) national contracts that expand its ... services at lower costs. These include manufacturer product and ... initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), ... to develop treatments in areas of oncology, cancer supportive ... service global public relations firm, to support its media ... media communications outreach program primarily aimed at introducing MuGard ...
... China, Aug. 5, 2011 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore ... "Company"), the largest drugstore chain in China based on the ... will report its second quarter fiscal year 2011 financial results ... The Company will host a conference call, to be ...
Cached Medicine Technology:Access Pharmaceuticals Retains Edelman as Public Relations Firm 2Access Pharmaceuticals Retains Edelman as Public Relations Firm 3China Nepstar Chain Drugstore to Report Second Quarter 2011 Financial Results on August 23 2
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... of Catholics for Choice, issued the following statement on Respect ... Catholic Bishops holds its annual Respect Life Sunday. On this ... also respect the truth. A recent publication by the USCCB, ... on healthcare reform prove that the bishops, desire to promote ...
... , WILMINGTON, Del., Oct. 2 Nationwide Health ... of 4,000 production transactions processed through the NHIN ... CONNECT solution. , CONNECTfx was developed ... NHIEs, HIEs, and other collaborative healthcare organizations by ...
... NASHVILLE, Tenn., Oct. 2 Brookdale Senior Living Inc. (NYSE: ... Chief Financial Officer, will make a presentation regarding the Company ... New York on Monday, October 5, 2009, beginning at 3:30 ... live and can be accessed on the Internet at ...
... risk rises when transfused blood is more than 28 days old, ... suffered severe trauma and are given a major transfusion of red ... are twice as likely to die as those who receive fresher ... of 202 severe trauma patients who were treated with five or ...
... Oct. 2 Brent Phillips, a senior executive at ... officer of Aurora Medical Group. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ... the 960-physician medical group. , "Brent will ... Jeff Bailet, M.D., president of Aurora Medical Group. ...
... a long way in the last decade. Today, one can talk, ... even access the Web. Now imagine a cell phone that can ... test water quality after a major disaster like a hurricane or ... engineering at UCLA,s Henry Samueli School of Engineering and Applied Science, ...
Cached Medicine News:Health News:Respect Life and the Truth on Respect Life Sunday 2Health News:Respect Life and the Truth on Respect Life Sunday 3Health News:NHIT Processes Over 4,000 Production Transactions, Advances Adoption of NHIN Initiative 2Health News:Fresh Blood Boosts Survival in Trauma Patients 2Health News:Mayo Clinic Executive Brent Phillips to Join Aurora Medical Group as Chief Operating Officer 2Health News:NIH recognizes engineering professor's innovative research with major award 2Health News:NIH recognizes engineering professor's innovative research with major award 3
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Intermittent catheter...
Medicine Products: